Back

Dosing and safety profile of aficamten in symptomatic obstructive hypertrophic cardiomyopathy: results from SEQUOIA-HCM

13 May 2024 (14:33 - 14:41)
Organised by: Logo
Congress Presentation Part of: Late breaking clinical trials: LVAD, HFpEF and hypertrophic cardiomyopathy Hypertrophic Cardiomyopathy HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Caroline Coats

University of Glasgow, Glasgow (United Kingdom of Great Britain & Northern Ireland)

9 More presentations in this session

Presentation thumbnail
Outcomes with aspirin avoidance after implantation of a Fully Magnetically Levitated LVAD in patients with coronary, cerebral or peripheral vascular disease: the ARIES HM3 randomized clinical trial
Professor F. Gustafsson (Pleasanton, US)
Slides Video
Presentation thumbnail
Discussant review - ARIES
Doctor O. Dar (London, GB)
Slides Video
Presentation thumbnail
Semaglutide therapy and diuretic use in obesity-related HFpEF: insights from the STEP-HFpEF programme
Professor S. Verma (Toronto, CA)
Slides Video
Presentation thumbnail
Discussant review - STEP-HFpEF Programme
Assistant Professor D. Farmakis (Athens, GR)
Slides Video
Presentation thumbnail
Aficamten for the treatment of symptomatic obstructive hypertrophic cardiomyopathy: SEQUOIA-HCM an international multicenter phase 3 trial
Doctor M. Maron (Burlington, US)
Slides Video

Access the full session

Session thumbnail
Late breaking clinical trials: LVAD, HFpEF and hypertrophic cardiomyopathy
Video

The Event

Event poster

Heart Failure 2024

13 May 2024 14:33 CET
You may be interested in
thumbnail
Congress Session
Late breaking clinical trials: LVAD, HFpEF and hypertrophic cardiomyopathy

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources